BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PROLOR Biotech (PBTH) to Present at Oppenheimer 23rd Annual Healthcare Conference


12/10/2012 10:10:22 AM

NES-ZIONA, Israel, Dec. 10, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT:PBTH) today announced that company management will give a corporate presentation at the Oppenheimer 23rd Annual Healthcare Conference on December 12, 2012 at 9:25 am EST. The conference is being held December 12-13, 2012 at the Waldorf Astoria Hotel in New York City.

A live webcast of the company's presentation will be available at http://www.veracast.com/webcasts/opco/healthcare2012/14104417.cfm. An archived version of the webcast will be available for 90 days beginning about three hours after the live presentation.

For more information about the Oppenheimer 23rd Annual Healthcare Conference, visit http://www.opco.com/Conferences/healthcare12/index.html.

ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development. For more information, visit www.prolor-biotech.com.

PROLOR CONTACT:

MEDIA CONTACT:

Shai Novik, President

Barbara Lindheim

PROLOR Biotech, Inc.

BLL Partners, LLC

Tel: +1 866 644-7811

+1 212 584-2276

Email: shai@prolor-biotech.com

blindheim@bllbiopartners.com

SOURCE PROLOR Biotech, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES